BEVACIZUMAB

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Zirabev®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Pfizer Australia Pty Ltd
Condition/indication: (therapeutic use): Advanced International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer; Advanced carcinoma of cervix; Relapsed or recurrent glioblastoma; Stage IV (metastatic) non-small cell lung cancer (NSCLC); Metastatic colorectal cancer.
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (Minor)
Comment:: --
Other PBAC consideration:: --

Progress Details

Submission received for:: July 2020 PBAC meeting
Opportunity for consumer comment:: Has not yet commenced
PBAC meeting:: Held on 08/07/2020
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

PBAC Public Summary Documents – July 2020

Case ID

a171

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19